The European Medicines Agency has announced approval of a new mid to late stage Parkinson's drug called Ongentys (opicapone) [1]. I generalize a lot, but put simply opicapone (taken in addition to C/L) is better than Stalevo, which is better than Sinemet, which is, in turn, better than plain levodopa.

Results show "off" times, per day, reduced by almost 2 hours compared with patients on Sinemet.

Opicapone will allow PwP to have smoother levels of levodopa, which should stop dyskinesia becoming a problem for longer.

Opicapone does not cure or slow the underlying progression of the disease.

Reference:

[1] http://www.ema.europa.eu/docs/en_GB/...C500209539.pdf

John